Table 1 Demographic and clinical data of patients and controls
PSA patients (70) | Controls (70) | P value | |
|---|---|---|---|
Age (years) | 40.85 ± 6.85 | 38.94 ± 7.17 | 0.1 |
Gender: (male/female) | 33/37 | 34/36 | 0.8 |
BMI | 27.91 ± 2.74 | 27.54 ± 2.27 | 0.38 |
Smokers: (Y/N) | 18/52 | 16/54 | 0.15 |
Duration of PSO (years) | 7.25 ± 3.75 | NA | |
Duration of PSA (years) | 3.74 ± 1.63 | NA | |
Treatment received: | |||
Methotrexate | 43 | NA | |
Sulphasalazine | 6 | ||
Anti-TNF | 14 | ||
IL-17 inhibitor | 26 | ||
Systolic blood pressure (mmHg) | 125.38 ± 10.5 | 128.03 ± 11.06 | 0.14 |
Diastolic blood pressure (mmHg) | 72.53 ± 9.06 | 70.71 ± 7.85 | 0.2 |
DAPSA score | 11.65 ± 6.82 | ||
Remission (n) | 8 | NA | |
Low disease activity (n) | 40 | ||
Moderate disease activity (n) | 20 | ||
Severe disease activity (n) | 2 | ||